Baxter International Inc. (BAX) News
Filter BAX News Items
BAX News Results
|Loading, please wait...|
BAX News Highlights
- BAX's 30 day story count now stands at 14.
- Over the past 23 days, the trend for BAX's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- HUBS, NOTE and NOV are the most mentioned tickers in articles about BAX.
Latest BAX News From Around the Web
Below are the latest news stories about BAXTER INTERNATIONAL INC that investors may wish to consider to help them evaluate BAX as an investment opportunity.
The U.S. health regulator on Wednesday classified the recall of hospital bed systems by Baxter International Inc, as the most serious type, on concerns it could lead to life-threatening injuries or death. Baxter initiated the recall of its WatchCare Incontinence Management System, which is used to discreetly alert an incontinent patient’s caregiver of involuntary urination […]
The U.S. Food and Drug Administration ((FDA)) announced Wednesday that Baxter International (BAX) had recalled more than 8,500 WatchCare Incontinence Management Systems after finding…
The U.S. health regulator on Wednesday classified the recall of hospital bed systems by Baxter International Inc, as the most serious type, on concerns it could lead to life-threatening injuries or death. Baxter initiated the recall of its WatchCare Incontinence Management System, which is used to discreetly alert an incontinent patient's caregiver of involuntary urination or defecation, by sending a correction letter to its customers in late September. In the letter, Baxter warned users about the potential for WatchCare's radio frequencies to interfere with other medical devices.
Do you want to know where to find good stock? Take a look at Baxter International Inc.’s (NYSE:BAX) Sentiment Analysis
Currently, Baxter International Inc.’s (BAX) stock is trading at $54.89, marking a gain of 1.05% from last night’s close. At this price, the stock is -38.81% below its 52-week high of $89.70 and 10.15% above its 52-week low of $49.83. Based on the past 30-day period, the stock price is -5.42% below the high and […]
Baxter International Inc. ( NYSE:BAX ) has announced that it will pay a dividend of $0.29 per share on the 3rd of...
Supply-chain tentacles have held the medical device-making industry in a tight grip. However, this may present upside potential for industry players like Baxter International (NYSE:BAX) and Abbott Labs (NYSE:ABT). The pandemic saw large numbers of patients deferring key medical and surgical procedures due to the lockdowns and the scare of visiting hospitals, which were the hubs of the virus. However, now, medical-device manufacturers are struggling to meet the inflated pent-up demand. The sporadic resurgences of COVID cases in the U.S. have kept the demand for medical devices up as well. The journey from glut to shortage of medical devices has been accelerated by the supply-chain snarls.
Ventricle Assist Devices (Vad) Market to Witness Huge Growth by Key Players: Xenios AG, Terumo Heart, Nikkiso, Baxter International, Jarvik Heart, St Jude Medical
The Ventricle Assist Devices (Vad) research report studies primary and secondary research in order to analyze the data effectively. The market study further also draws attention to crucial industry factors such as global clients, potential customers, and sellers, which instigates
DEERFIELD, Ill., November 16, 2022--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time.
DEERFIELD, Ill., November 15, 2022--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on January 3, 2023, to shareholders of record as of December 2, 2022. The indicated annual dividend rate is $1.16 per share of common stock.
Baxter Highlights New Home Dialysis and HDx Therapy Data in 14 Clinical Presentations at Kidney Week 2022
Controlled study at 21 hospitals shows remote patient management reduces adverse events for home peritoneal dialysis patientsNew ex vivo study demonstrates superior performance of the Theranova dialyzer in effectively balancing higher removal of large middle-molecule toxins and albumin stability during hemodialysis DEERFIELD, Ill., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Baxter International Inc. (NYSE:BAX), a global innovator in kidney care, advanced scientific exchange with 14 new data presentations